Logo Medical Science Monitor

Call: +1.631.470.9640
Closed: National Holiday

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 June 2012

A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular degeneration

Michał S. NowakABCDEF, Piotr JurowskiAD, Andrzej GrzybowskiEF, Roman GośA, Mirosław PastuszkaB, Andrzej KapicaB, Janusz ŚmigielskiC

DOI: 10.12659/MSM.882907

Med Sci Monit 2012; 18(6): CR374-380

Abstract

Background: The aim of this study was to compare the efficacy of verteporfin photodynamic therapy (PDT), intravitreal injections of bevacizumab (IVB) and transpupillary thermotherapy (TTT) in patients with neovascular age-related macular degeneration (AMD).
Material/Methods: The study design was a prospective, interventional, comparative case series. Between December 2006 and March 2009, 426 eyes of 426 consecutive patients presenting with neovascular AMD were included into the study. Patients presented with subfoveal CNV predominantly classic, minimally classic, and occult with no classic component; lesion size less than 5000 µm in the greatest linear dimension, and the area of hemorrhages ≤1/3 were randomized to receive either PDT (group I) or IVB (group II) in a 1:1 ratio. Other patients with CNV were included into the group III and received TTT.
Results: One hundred eyes were treated with PDT. Mean baseline logMAR BCVA was 0.62 and final visual acuity decreased to 0.74 (p<0.05, Wilcoxon test); 104 eyes were treated with IVB. Mean baseline BCVA was 0.82 and final visual acuity increased to 0.79 (p>0.05, Wilcoxon test); 222 patients were treated with TTT. Mean baseline BCVA was 1.10 and final visual acuity decreased to 1.15 (p>0.05, Wilcoxon test). Among all eyes the average number of treatment sessions was 2.34 (SD 1.17).
Conclusions: Our study shows that IVB injections had the best efficacy in the improvement of final BCVA. However, both IVB and TTT demonstrated good stabilization of vision. Although after PDT final BCVA was significantly worse from baseline, it may also be beneficial for some patients with neovascular age-related macular degeneration.

Keywords: Photosensitizing Agents - therapeutic use, Porphyrins - therapeutic use, Photochemotherapy, Macular Degeneration - physiopathology, Intravitreal Injections, Hyperthermia, Induced - methods, Demography, Choroidal Neovascularization - physiopathology, Antibodies, Monoclonal, Humanized - therapeutic use, Aged, 80 and over, Prospective Studies, Pupil - drug effects, Visual Acuity - drug effects

Add Comment 0 Comments

Editorial

01 January 2025 : Editorial  

Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?

Dinah V. Parums

DOI: 10.12659/MSM.947707

Med Sci Monit 2025; 31:e947707

0:00

In Press

Clinical Research  

Butorphanol Tartrate Nasal Spray for Post-Cesarean Analgesia and Prolactin Secretion

Med Sci Monit In Press; DOI: 10.12659/MSM.945224  

Database Analysis  

Role of the Carhart Effect and Outcomes from Surgery: A Retrospective Study of 532 Patients with Conductive...

Med Sci Monit In Press; DOI: 10.12659/MSM.947061  

Clinical Research  

Factors Affecting Medication Adherence in Middle-Aged and Elderly Patients in China: A Cross-Sectional Study

Med Sci Monit In Press; DOI: 10.12659/MSM.945805  

Review article  

Characteristics and Associated Risk Factors of Broad Ligament Hernia: A Systematic Review

Med Sci Monit In Press; DOI: 10.12659/MSM.946710  

Most Viewed Current Articles

17 Jan 2024 : Review article   6,963,278

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   700,194

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Mar 2024 : Editorial   23,571

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...

DOI :10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

28 Jan 2024 : Review article   18,228

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

DOI :10.12659/MSM.943912

Med Sci Monit 2024; 30:e943912

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750